Key Takeaways

  • The FDA granted RDEP designation to NanoRetinal’s NAR-001 for RLBP1-associated retinal dystrophy

  • NAR-001 is an investigational intravitreal therapy designed to restore retinal visual pigment without genetic modification

The FDA has granted Rare Disease Evidence Principles (RDEP) designation to NanoRetinal Inc.’s NAR-001, an investigational nanoparticle-based therapy being developed for RLBP1-associated retinal dystrophy, a rare inherited retinal disease.

The designation, granted through the FDA’s Center for Drug Evaluation and Research (CDER), provides a regulatory framework intended to facilitate the development and approval of treatments for genetically defined diseases affecting very small patient populations.

Under the RDEP framework, substantial evidence of effectiveness may generally be established through one adequate and well-controlled study, supported by robust confirmatory evidence of a treatment effect.

NanoRetinal’s lead candidate, NAR-001, is designed to restore retinal visual pigment and preserve vision in patients with inherited retinal diseases, including certain forms of retinitis pigmentosa (RP).

The investigational therapy uses an intravitreal protein-based approach intended to restore the visual cycle without genetic modification. According to the company, NAR-001 is engineered to increase the availability, photostability, and durability of visual pigment, which can be impaired by genetic mutations associated with RP.

“We are thrilled with the RDEP designation and our chance to help prevent blindness by treating patients with the RLBP-1 retinal disease,” said John Cullity, MD, CEO of NanoRetinal. “Our patented technology restores retinal visual pigment helping preserve vision for RP patients.”

The FDA introduced the RDEP framework in September 2025 to address regulatory challenges associated with developing treatments for rare diseases characterized by significant unmet medical needs and known genetic defects.

NanoRetinal said NAR-001 qualified for the framework because it targets a specific genetic defect for which no approved therapy currently exists.

Based at Princeton Innovation Center BioLabs in Princeton, New Jersey, NanoRetinal is developing nanoparticle-based treatments using technology licensed from the University of Bern in Switzerland.